Posted by Michael Wonder on 17 Dec 2024
ICER publishes final evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
16 December 2024 - Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tabelecleucel when compared to usual care; tabelecleucel would achieve common thresholds for cost effectiveness if priced between $143,900 - $273,700 per treatment cycle.
The ICER today released a final evidence report assessing the comparative clinical effectiveness of tabelecleucel (Pierre Fabre) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease.
